```html

Localized Scleroderma (Morphea) – A Comprehensive Guide

Overview

Localized scleroderma, most commonly known as morphea, is an autoimmune skin disorder in which excess collagen builds up in the skin and, sometimes, the underlying tissue. Unlike systemic sclerosis, morphea generally does not affect internal organs, but it can cause significant cosmetic disfigurement, functional limitation, and emotional distress.

• Typical age of onset: 5–15 years (childhood) and 40–60 years (adulthood). A second smaller peak occurs in women of reproductive age.
• Gender: Women are affected roughly 2–3 times more often than men.
• Prevalence: Estimates range from 2–3 cases per 100,000 people in the United States, with similar rates reported in Europe and Asia (Mayo Clinic; NIH).
• Ethnicity: Occurs in all races, though some studies suggest a slightly higher incidence in people of Northern European descent.

Symptoms

Morphea manifests in a spectrum of skin changes. The presentation can be subtle at first and may evolve over months or years.

Cutaneous signs

• Plaques: Raised, thickened, oval or round patches of skin that feel firm to the touch. They are often ivory‑white or pink‑red in color.
• Linear lesions: Bands of skin tightening that run along a line—commonly on the limbs or trunk. When they cross joints, they can restrict movement.
• Atrophied “cigarette‑paper” skin: Over time the affected skin becomes thin, shiny, and may develop a wrinkled appearance.
• Hyperpigmentation or hypopigmentation: The skin may become darker or lighter than surrounding areas.
• Hair loss (alopecia): Hair may fall out from the affected patch.

Musculoskeletal involvement

• Joint stiffness or limited range of motion when plaques overlie a joint.
• Muscle weakness or atrophy if deep fascia is involved (deep morphea).

Other possible features

• Itching or burning sensation in the early, active phase.
• Sunlight may worsen the rash (photosensitivity).
• Rarely, underlying bone may become softened (osteolysis) or develop abnormal growths.

Causes and Risk Factors

The exact trigger for morphea is unknown, but research points to a combination of genetic susceptibility, immune dysregulation, and environmental exposures.

Possible causes

• Autoimmune activity: The body’s immune system mistakenly attacks skin fibroblasts, leading to excess collagen production.
• Genetic predisposition: Certain HLA (human leukocyte antigen) subtypes, such as HLA‑DRB1*04, have been linked to a higher risk.
• Environmental triggers: Reports associate morphea with trauma, infections (e.g., Borrelia burgdorferi), radiation therapy, and certain medications (e.g., bleomycin).
• Infections: Some viral (Parvovirus B19) and bacterial infections have been identified in case‑control studies, though causality remains uncertain.

Risk factors

• Female gender
• Family history of autoimmune disease (e.g., lupus, rheumatoid arthritis)
• Personal history of other autoimmune conditions
• Recent skin injury or surgical scar at the site of a future lesion
• Living in climates with high ultraviolet exposure (possible photosensitivity component)

Diagnosis

Diagnosing morphea involves a careful clinical exam, supportive laboratory tests, and sometimes imaging or biopsy.

Clinical evaluation

• Physical exam to document size, shape, location, and depth of plaques.
• Assessment of joint range of motion and muscle strength.
• Photographic documentation for monitoring progression.

Laboratory tests

• Autoantibody panels: ANA (antinuclear antibody) is positive in ~30 % of patients; specific antibodies (e.g., anti‑centromere) are less common than in systemic sclerosis.
• Inflammatory markers (ESR, CRP) may be mildly elevated during active disease.
• Complete blood count and metabolic panel to rule out other systemic conditions.

Skin biopsy

Performed when the diagnosis is uncertain. Histology typically shows thickened collagen bundles, loss of adnexal structures, and a perivascular inflammatory infiltrate.

Imaging (when needed)

• Ultrasound or MRI: Evaluate depth of involvement, especially for deep morphea affecting fascia or muscle.
• X‑ray: Detect bone changes (e.g., cortical thinning) if joint or bone involvement is suspected.

Diagnostic criteria

The American College of Rheumatology (ACR) recommends a combination of clinical features and, when necessary, histopathology to confirm morphea. A diagnosis is usually made without the need for extensive testing unless systemic involvement is a concern.

Treatment Options

There is no cure, but several therapies can halt progression, soften plaques, and improve functional outcomes.

Topical therapies

• High‑potency corticosteroids (e.g., clobetasol 0.05%): Reduce inflammation in early, active lesions. Applied once or twice daily for 2–4 weeks.
• Topical tacrolimus (0.1%): Useful for sensitive areas (face, neck) where steroids may cause atrophy.
• Calcipotriene: Vitamin D analog that may modulate fibroblast activity.

Phototherapy

• UVA1 (340–400 nm): The most evidence‑based light therapy for morphea. Typical regimen: 3–5 sessions per week for 6–12 weeks, delivering 30–50 J/cm² per session.
• PUVA (psoralen + UVA): Alternative when UVA1 is unavailable; however, it carries a higher risk of skin cancer with long‑term use.

Systemic medications

• Methotrexate (MTX): First‑line oral or subcutaneous agent for moderate‑to‑severe disease. Dose: 15–25 mg/m² weekly, often combined with low‑dose prednisone.
• Mycophenolate mofetil (MMF): Effective for deep morphea or refractory cases; typical dose 1–2 g/day divided BID.
• Ciclosporin: Considered when MTX is contraindicated.
• Systemic corticosteroids: Short courses (e.g., prednisone 0.5–1 mg/kg/day for 4–6 weeks) may be used to rapidly control active inflammation before transitioning to a steroid‑sparing agent.

Physical and occupational therapy

Therapists provide stretching exercises, splinting, and functional training to prevent contractures, especially in linear lesions crossing joints.

Surgical options

• Release procedures: Tendon lengthening or contracture release for severe joint restriction.
• Skin grafting or flap reconstruction: Considered for extensive atrophic scars after disease inactivity.

Adjunctive measures

• Moisturizers and emollients to maintain skin barrier.
• Sun protection (broad‑spectrum SPF 30+) to limit photosensitivity‑related flare‑ups.
• Regular monitoring for new lesions or functional decline.

Living with Localized Scleroderma (Morphea)

Successful long‑term management combines medical treatment with practical daily habits.

Skin care routine

• Gentle, fragrance‑free cleansers; avoid harsh scrubbing.
• Apply a thick, oil‑based moisturizer (e.g., ceramide‑rich cream) twice daily.
• Use silicone gel sheets or silicone scar gels once lesions are inactive to improve texture.

Exercise and mobility

• Daily range‑of‑motion stretches, especially for limbs with linear plaques.
• Low‑impact activities (walking, swimming, yoga) maintain joint health without stressing the skin.
• Consult a physical therapist for a personalized program.

Psychosocial support

• Join support groups (e.g., Scleroderma Foundation’s online communities).
• Consider counseling or cognitive‑behavioral therapy to address body‑image concerns.
• Educate family, teachers, and coworkers about the condition to reduce stigma.

Monitoring & follow‑up

• Schedule dermatology or rheumatology appointments every 3–6 months during active disease; annual visits may suffice once stable.
• Track lesion size and symptoms with a journal or phone app.
• Report any new joint pain, swelling, or functional loss promptly.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, risk can be lowered by:

• Promptly treating skin injuries (cuts, burns) and avoiding unnecessary trauma.
• Maintaining good sun protection habits.
• Managing infections promptly; consider treatment for Lyme disease if you live in endemic areas.
• Regular health checks for individuals with a personal or family history of autoimmune disease.

Complications

If left uncontrolled, morphea can lead to several health problems:

• Joint contractures: Particularly with linear lesions over elbows, knees, or fingers, limiting mobility.
• Muscle atrophy or weakness: Deep morphea affecting fascia.
• Functional impairment: Difficulty performing daily activities such as writing, dressing, or driving.
• Cosmetic disfigurement: Persistent atrophic scars may cause psychological distress.
• Secondary infections: Breakdowns in the skin barrier can predispose to cellulitis.
• Rare systemic involvement: About 2–5 % of patients develop features of systemic sclerosis (e.g., internal organ fibrosis), warranting closer surveillance.

When to Seek Emergency Care

References

• Mayo Clinic. “Morphea (localized scleroderma).” https://www.mayoclinic.org (accessed April 2026).
• National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Scleroderma Fact Sheet.” https://www.niams.nih.gov.
• Cleveland Clinic. “Localized Scleroderma (Morphea).” https://my.clevelandclinic.org.
• World Health Organization. “Autoimmune diseases: Global burden.” WHO Bulletin 2022;100(12):987‑994.
• Wong R, et al. “UVA1 phototherapy for morphea: a systematic review.” *J Am Acad Dermatol*. 2021;85(3):645‑655.
• Gordon M, et al. “Methotrexate in the treatment of pediatric and adult morphea.” *Dermatology*. 2020;236(2):123‑131.

```